Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: November 3, 2011
Last updated: November 21, 2014
Last verified: October 2014

November 3, 2011
November 21, 2014
October 2011
June 2015   (final data collection date for primary outcome measure)
  • Objective response rate (CR and PR) [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]
  • PFS [ Time Frame: From date of registration to date of first observation of progressive disease or death due to any cause, assessed up to 1 year ] [ Designated as safety issue: No ]
  • Toxicity as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [ Time Frame: Up to 2 years ] [ Designated as safety issue: Yes ]
  • Objective response rate (CR and PR) [ Designated as safety issue: No ]
  • Overall survival [ Designated as safety issue: No ]
  • 1-year PFS [ Designated as safety issue: No ]
  • Toxicity [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT01466881 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma

This phase II trial studies how well alisertib works in treating patients with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma. Alisertib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.


I. To estimate the objective response rate (complete responses [CR] + partial responses [PR]) after 4 courses of treatment with alisertib (MLN8237) in patients with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma.

II. To assess overall survival (OS) and progression-free survival (PFS) in this patient population.

III. To evaluate the safety and tolerability of MLN8237 treatment for this patient population.

IV. To explore the association between pre-treatment aurora kinase A expression in tumor biopsies as measured by fluorescence in situ hybridization (FISH) and objective response rate in patients with peripheral T-cell lymphomas (PTCL) treated with MLN8237. (exploratory) IV. To investigate the copy number, mutational status, expression of aurora kinase (A, B, and C) and associated signaling pathways in PTCL utilizing tissue microarray analysis (TMA) before and after treatment with MLN8237.


I. To investigate changes in the serum cytokine profile pre- and post- aurora kinase Inhibitor treatment.

II. To evaluate serum markers of apoptosis pre- and post- aurora kinase inhibitor treatment as pharmacodynamic markers of efficacy.


Patients receive alisertib orally (PO) twice daily (BID) on days 1-7. Treatment repeats every 21 days for 17 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 4 months for 2 years.

Phase 2
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Adult Nasal Type Extranodal NK/T-Cell Lymphoma
  • Anaplastic Large Cell Lymphoma
  • Angioimmunoblastic T-Cell Lymphoma
  • Hepatosplenic T-Cell Lymphoma
  • Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
  • Recurrent Adult Non-Hodgkin Lymphoma
  • Recurrent Adult T-Cell Leukemia/Lymphoma
  • Drug: Alisertib
    Other Names:
    • Aurora A Kinase Inhibitor MLN8237
    • MLN-8237
    • MLN8237
  • Other: Pharmacological Study
    Other Name: pharmacological studies
  • Other: Laboratory Biomarker Analysis
    Correlative studies
Experimental: Treatment (alisertib)
Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for 17 courses in the absence of disease progression or unacceptable toxicity.
  • Drug: Alisertib
  • Other: Pharmacological Study
  • Other: Laboratory Biomarker Analysis
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Active, not recruiting
Not Provided
June 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients must have histologically or cytologically confirmed relapsed/refractory non-Hodgkin lymphoma (NHL) with any of the following T-cell histologies:

    • Peripheral T-cell NHL (PTCL) not otherwise specified (NOS)
    • Anaplastic large cell T-cell lymphoma (ALCL) that is anaplastic lymphoma kinase either positive or negative
    • Angioimmunoblastic T-cell NHL
    • Subcutaneous panniculitis-like T-cell lymphoma
    • Enteropathy-associated T-cell NHL
    • Hepatosplenic T-cell lymphomas
    • Extranodal NK/T-cell lymphoma, nasal type
    • Adult T-cell leukemia/lymphoma
    • Unclassifiable PTCL
    • Transformed cutaneous T-cell lymphoma (CTCL) to PTCL with systemic involvement (not local skin transformation)
    • No other histologies are eligible; examples of ineligible histologies include: T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia, NK-cell leukemia, mycosis fungoides, Sezary syndrome, lymphomatoid papulosis, and primary CTCL
  • Patients must have received at least one course of prior systemic therapy which may include chemotherapy, antibody therapy, or immunotherapy; for all forms of systemic therapy, patients must have completed therapy at least 21 days prior to registration; patients must not be within 84 days of radioimmunotherapy; steroids at a low dose for control of itching (up to the equivalent of 20 mg of prednisone daily) are allowed
  • Adequate sections and a paraffin block from the relapsed/refractory specimen must be submitted for review by the lymphoma pathology group; an adequate biopsy requires sufficient tissue to establish the architecture and a Revised European American Lymphoma (REAL) or World Health Organization (WHO) histologic subtype with certainty; thus, core biopsies, especially multiple core biopsies MAY be adequate; whereas, needle aspirations or cytologies are not adequate
  • Patients must have bidimensionally measurable disease

    • Patients who also have non-measurable disease in addition to measurable disease must have all non-measurable disease assessed within 42 days prior to registration
  • Patients must have a bilateral or unilateral bone marrow aspirate and biopsy performed within 42 days prior to registration
  • Patients must not have clinical evidence of central nervous system involvement by lymphoma
  • Patients must be able to swallow tablets
  • Patients known to be human immunodeficiency virus (HIV)-positive must not have multi-drug resistant HIV infection, CD4 counts < 150/mcL, or other concurrent acquired immunodeficiency syndrome (AIDS)-defining conditions
  • Absolute granulocyte count >= 1,000 cells/mcL
  • Platelet count >= 75,000 cells/mcL (patients with documented marrow involvement may be transfused to this value)
  • Serum bilirubin =< 2 times institutional upper limit of normal
  • Patients must have a Zubrod performance status of 0, 1, or 2
  • No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years
  • Pregnant or nursing women may not participate
  • Women or men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
  • Patients may have received prior radiation in combination with systemic therapy; patients must not be within 21 days of external-beam radiation therapy
  • Patients must not have received a previous allogeneic stem cell transplant or be within 90 days of an autologous stem cell transplant
18 Years and older
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
NCI-2011-03551, NCI-2011-03551, SWOG-S1108, CDR0000714328, S1108, S1108, U10CA032102
Not Provided
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Not Provided
Principal Investigator: Paul Barr Southwest Oncology Group
National Cancer Institute (NCI)
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP